The short version of drug affinity complex fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-07. Anything still debated is marked as such rather than presented as settled.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | GHRH receptor agonist |
| Sequence length | 29 amino acids | Derived from human GHRH |
| Molecular weight | About 3368 Da without linker | Albumin-binding form is heavier |
| Appearance | White to off-white lyophilized powder | Common form for research reference material |
| Typical storage | -20 °C or below, desiccated | Protect powder from light and moisture |
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The third stage of labor describes the period between the birth of the baby and the delivery of the placenta, which normally lasts less than 30 minutes. The delivery of the placenta causes an abrupt drop off of placental hormones. This drop, specifically in progesterone, allows prolactin to work effectively at its receptors in the breast, leading to an array of changes over the next several days that allow the milk to "come in"; these changes are known collectively as Lactogenesis II. Colostrum continues to be produced for these next few days, as Lactogenesis II occurs. Milk may "come in" as late as five days after delivery; however, this process may be delayed due to a number of factors as described in the Process "Delay in milk 'coming in'" subsection below. Oxytocin, which signals the smooth muscle of the uterus to contract during pregnancy, labor, birth and following delivery, is also involved in the process of breastfeeding. Oxytocin also contracts the smooth muscle layer of band-like cells surrounding the milk ducts and alveoli to the newly produced milk through the duct system and out through the nipple. This process is known as the milk ejection reflex, or let-down. Because of oxytocin's dual activity at the breast and the uterus, breastfeeding mothers may also experience uterine cramping at the time of breastfeeding, for the first several days to weeks.
=== Kinetic exclusion assay === Kinetic exclusion assay (KinExA) measures free (unbound) ligand or free receptor present in a mixture of ligand, receptor, and ligand-receptor complex. The measurements allow quantitation of the active ligand concentration and the binding constants (equilibrium, on and off rates) of the interaction.
Taurine is partially destroyed by heat in processes such as baking and boiling. This is a concern for cat food, as cats have a dietary requirement for taurine and can easily become deficient. Either raw feeding or supplementing taurine can satisfy this requirement. Both lysine and taurine can mask the metallic flavor of potassium chloride, a salt substitute.
Since the war, the US has had a continued presence of 5,000 troops stationed in Saudi Arabia – a figure that rose to 10,000 during the 2003 conflict in Iraq. Operation Southern Watch enforced the no-fly zones over southern Iraq set up after 1991; oil exports through the Persian Gulf's shipping lanes were protected by the Bahrain-based US Fifth Fleet. Since Saudi Arabia houses Mecca and Medina, Islam's holiest sites, many Muslims were upset at the permanent military presence. The continued presence of U.S. troops in Saudi Arabia after the war was one of the stated motivations behind the 11 September terrorist attacks, the Khobar Towers bombing, and the date chosen for the 1998 US embassy bombings (7 August), which was eight years to the day that US troops were sent to Saudi Arabia. Osama bin Laden interpreted the Islamic prophet Muhammad as banning the "permanent presence of infidels in Arabia". In 1996, bin Laden issued a fatwa, calling for US troops to leave Saudi Arabia. In a December 1999 interview with Rahimullah Yusufzai, bin Laden said he felt that Americans were "too near to Mecca" and considered this a provocation to the entire Islamic world.
Sources: en.wikipedia.org
== The Monolith Summer School == Since 2004, BIA Separations has organized and hosted the Monolith Summer School and Symposium (MSS) which takes place every 2 years. MSS was established as there were no dedicated conferences to this technology and to bring together the top international scientists and researchers in the area of monolith chromatography to share their experiences and innovative applications.
=== Formylation reactions in purine biosynthesis === Two formylation reactions are required in the eleven step de novo synthesis of inosine monophosphate (IMP), the precursor of the purine ribonucleotides AMP and GMP. Glycinamide ribonucleotide (GAR) transformylase catalyzes the formylation of GAR to formylglycinamidine ribotide (FGAR) in the fourth reaction of the pathway. In the penultimate step of de novo purine biosynthesis, 5-aminoimidazole-4-carboxyamide ribotide (AICAR) is formylated to 5-formaminoimidazole-4-carboxamide ribotide (FAICAR) by AICAR transformylase.
==== Syria sanctions ==== Bush expanded economic sanctions on Syria. In 2003, Bush signed the Syria Accountability Act, which expanded sanctions on Syria. In early 2007, the Treasury Department, acting on a June 2005 executive order, froze American bank accounts of Syria's Higher Institute of Applied Science and Technology, Electronics Institute, and National Standards and Calibration Laboratory. Bush's order prohibits Americans from doing business with these institutions suspected of helping spread weapons of mass destruction and being supportive of terrorism. Under separate executive orders signed by Bush in 2004 and later 2007, the Treasury Department froze the assets of two Lebanese and two Syrians, accusing them of activities to "undermine the legitimate political process in Lebanon" in November 2007. Those designated included: Assaad Halim Hardan, a member of Lebanon's parliament and former leader of the Syrian Socialist National Party; Wi'am Wahhab, a former member of Lebanon's government (Minister of the Environment) under Prime Minister Omar Karami (2004–2005); Hafiz Makhluf, a colonel and senior official in the Syrian General Intelligence Directorate and a cousin of Syrian president Bashar al-Assad; and Muhammad Nasif Khayrbik, identified as a close adviser to Assad.
Sources: en.wikipedia.org
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.
The label was first attached to the albumin-binding form during early development work. A shorter analog without the linker later became known by the same name in informal use. Published papers normally state which version was studied, so the methods section resolves the ambiguity.
It is a synthetic peptide rather than a steroid, and it does not occur naturally in the body. Its sequence is derived from a hypothalamic hormone called growth hormone-releasing hormone. It works as a receptor agonist rather than as a replacement for that hormone.
The powder is normally held at minus twenty degrees Celsius or below. Light and moisture exposure should be minimized. Repeated warming and cooling cycles are avoided.